

Special Issue

Skin Diseases: From Accurate Diagnosis to Novel Therapeutic Approaches, in the Light of Molecular Medicine

Message from the Guest Editor

Medicine in general, and dermatology in particular, has recently made significant progress. A greater understanding of the molecular mechanisms led eventually to better and more accurate reclassifications in dermatology, the medical specialty that undoubtedly consists of the highest number and variety of diseases. In psoriasis, we are currently experiencing a spring in novel therapeutic approaches that are life-changing for our patients. Although psoriasis remains a problem, great steps forward have been made in understanding this genetic, inflammatory, immunological, proliferative disorder of keratinization. The efficiency of monoclonal antibodies in bullous diseases and melanoma has started a new era in our understanding of a tailor-made approach to the dermatological/rheumatological patient. Human skin is indeed a powerful and amazing immune organ. Cutaneous resident cells are fully equipped to provide the best protection of the other human cells' DNA. For example, if we analyse the keratinocyte, we will realize how diligent it can be during its turnover while participating in both acquired and innate immunity.

Guest Editor

Dr. Olga Simionescu

Chief of the First Clinic of Dermatology, Department of Dermatology, "Carol Davila" University of Medicine and Pharmacy, Colentina Hospital, 020125 Bucharest, Romania

Deadline for manuscript submissions

closed (31 January 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/105845

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).